Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. - Wikidata - awgldk - TriplyDB

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

http://www.wikidata.org/entity/Q35049845

about

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.A concise and practical stereoselective synthesis of ipragliflozin L-proline.Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse Pharmacotherapy with Thymoquinone Improved Pancreatic β-Cell Integrity and Functional Activity, Enhanced Islets Revascularization, and Alleviated Metabolic and Hepato-Renal Disturbances in Streptozotocin-Induced Diabetes in Rats.Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

P2860

Q36429733-B242EB00-FC9F-4E18-BC1B-2DBFF03CB980 Q37251449-EDA70577-F7F3-42A1-8A17-528AD9E0BBD2 Q38908779-622F162F-A4D0-4C48-9DF5-5C58305EDC11 Q41070264-B638AF45-B2BF-4DA0-93A4-9E4D208EA51B Q41579741-6248ECC8-A384-4C9E-B597-3F53FD42E1CF Q47778694-BA2C59ED-F478-413E-951B-FB6F87A95B31 Q51276351-67A4D4F5-0830-440C-9593-B2C41E68CC3C

P2860

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

http://www.wikidata.org/entity/Q35049845

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

@ast

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

@en

type

label

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

@ast

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

@en

prefLabel

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

@ast

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

@en

P1433

Q35049845-DB35FF90-7C38-4B9D-8963-A4A20B21861D

P1476

Q35049845-69F451B6-5C03-488F-94C3-2120121818EB

P2093

Q35049845-80DBDB94-DC72-4F8E-86F7-718D5541A9C6

P2860

Q35049845-123529C2-F7E7-40CF-9944-C31B4C2DC41A

Q35049845-13D1C0DA-1228-4C8E-9346-B8AF50640A1D

Q35049845-1531A7BC-3240-4749-9436-3CA4BA5DF91E

Q35049845-1AEFB14A-7CD6-42FF-A888-C37FF8835D1B

Q35049845-20B91F3A-359D-4905-B9B9-4C70085597D7

Q35049845-2329949C-7CCE-4E4D-9378-E7099ABCC0EF

Q35049845-244626A2-4F33-49EC-9C39-FCBFE7015796

Q35049845-289A2C0F-EC55-4BC3-A099-DD3941AA7618

Q35049845-2BD009FE-416C-4564-BBF0-F011A5F49DB5

Q35049845-31E23692-291D-4BC9-B2A5-6FCF185C7473

P304

Q35049845-26B2A0F7-D1EC-4B7A-B8B9-0AC73157F313

P31

Q35049845-4B7AF3D0-E5A1-40B3-AF30-D06016F8886D

P356

Q35049845-85BF3FA6-0E06-4376-937B-3A01DAD09368

P433

Q35049845-3D1DAB47-28E0-4336-B636-8384AA7101CC

P478

Q35049845-AD4271DE-5F73-4E96-9597-F8FC3DB30C79

P577

Q35049845-23228BDF-C253-470A-B9D8-F6F895681DCC

P5875

Q35049845-06DA504F-5218-4177-BDB4-12A7DA7EFB46

P698

Q35049845-8B48FD5A-791C-40A0-B9C8-B6C9E1367EB2

P932

Q35049845-28A2BF31-D3C3-44CD-B47D-C4E6EE1BF2E5

P356

P1433

World journal of diabetes

P1476

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

@en

P2093

Tsuyoshi Ohkura

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

The development of a new measure of quality of life for young people with diabetes mellitus: the ADDQoL-Teen

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

SGLT-2 inhibitors in development for type 2 diabetes treatment

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

P304

136-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4239/WJD.V6.I1.136

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272422107

http://www.w3.org/2001/XMLSchema#string

P698

25685284

http://www.w3.org/2001/XMLSchema#string

P932

4317305

http://www.w3.org/2001/XMLSchema#string